COMP <GO>
BVS vs TNDM // GROSS PROFIT MARGIN
Bioventus Inc. (Class A) (NASDAQ) VS. Tandem Diabetes Care Inc. (NASDAQ) • 15-METRIC TALLY: BVS 7
— TNDM 3
▲ GROSS PROFIT MARGIN LEADER: BVS
LAST: $14.87 (+1.50%) • MKT CAP: $1.25B
gross-margins
68.30%
LAST: $19.79 (+0.56%) • MKT CAP: $1.38B
gross-margins
53.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BVS VS. TNDM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BVS | TNDM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 68.30% | 53.80% | +14.50 | BVS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.40% | -35.00% | +45.40 | BVS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 26.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.77% | -2.15% | +7.92 | BVS | /fcf-yield <GO> |
| Operating Margin | 9.50% | -18.50% | +28.00 | BVS | /operating-margins <GO> |
| Net Profit Margin | 4.00% | -20.20% | +24.20 | BVS | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 7.90% | -8.80 | TNDM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.25 | 0.20 | +2.05 | BVS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 4/9 | +3.00 | BVS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.9 | 62.4 | -18.42 | TNDM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 51.2x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.25B | $1.38B | -$126.5M | TNDM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BVS REV | TNDM REV | BVS GROSS % | TNDM GROSS % | BVS FCF | TNDM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $568.1M | $1.01B | 68.3% | 53.8% | $72.1M | -$29.7M |
| FY 2024 | $573.3M | $940.2M | 67.7% | 52.1% | $37.8M | $5.0M |
| FY 2023 | $512.3M | $747.7M | — | — | $15.3M | -$31.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BVS // BETA —
TNDM // BETA —